SSG
VBIV

Summit Securities Group’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Summit Securities Group’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-17
Closed – – 1442
2022
Q3 		$0 Buy
+17
New +$458 ﹤0.01% 1218
2013
Q4 		– Sell
-38
Closed -$6K – 608
2013
Q3 		$6K Buy
+38
New +$7.4K ﹤0.01% 292

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Summit Securities Group's VBIV Position: Q4 2022 in Review

Summit Securities Group sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q4 2022, closing a stake of 17 shares.

Summit Securities Group first reported a position in VBIV in Q3 2013 and held it in 2 quarters. The position peaked at $6K in Q3 2013. 111 funds tracked by Wall St. Rank hold VBIV as of Q4 2022.

  • Summit Securities Group reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q4 2022 after selling out during the quarter.
  • Summit Securities Group sold 17 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q4 2022.
  • Summit Securities Group first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q3 2013 and held it in 2 quarters.
  • Summit Securities Group's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $6K in Q3 2013.
  • 111 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q4 2022.

Based on Summit Securities Group's 13F filing for Q4 2022, filed 13 Feb 2023.